Literature DB >> 27321887

Endovascular Treatment of Hepatic Artery Pseudoaneurysm after Pancreaticoduodenectomy: Risk Factors Associated with Mortality and Complications.

Tetsuya Hasegawa1, Hideki Ota2, Tomonori Matsuura2, Kazumasa Seiji2, Shunji Mugikura2, Fuyuhiko Motoi2, Michiaki Unno2, Kei Takase2.   

Abstract

PURPOSE: To evaluate risk factors predicting death and complications of primary therapy for hepatic and gastric duodenal artery pseudoaneurysms following endovascular treatment (EVT) after pancreaticoduodenectomy (PD).
MATERIALS AND METHODS: Between April 2004 and December 2014, 28 patients (mean age, 64.7 y) with post-PD hemorrhage underwent EVT. Prevention of hepatic artery blockage via stents or side-holed catheter grafts was stratified in cases without a replaced hepatic artery. Mortality and major hepatic complications following EVT were evaluated according to age; sex; surgery-EVT interval; presence of portal vein stenosis, shock, and coagulopathy at EVT onset; and post-EVT angiographic findings.
RESULTS: All hemorrhages were successfully treated with microcoils (n = 17; 61%), covered stents (n = 1; 3%), bare stent-assisted coil embolization (n = 5; 18%), or catheter grafts with coil embolization (n = 5; 18%). Hepatic arterial flow was observed after EVT in 18 patients (64%). Mortality and major hepatic complication rates were 28.6% and 32.1%, respectively. Hemorrhagic shock and coagulopathy at EVT onset (n = 8 each; odds ratio [OR], 27; 95% confidence interval [CI], 3.1-235.7; P < .01) were significantly associated with mortality. Coagulopathy at EVT onset (adjusted OR [aOR], 48.1; 95% CI, 3.2-2,931), portal vein stenosis (n = 16; aOR, 16.9; 95% CI, 1.3-721.9), and no visualization of hepatopetal flow through the hepatic arteries (n = 10; aOR, 29.5; 95% CI, 2.1-1,477) were significantly associated with major hepatic complications.
CONCLUSIONS: EVT should be performed as soon as possible before the development of shock or coagulopathy. Hepatic arterial flow visualization decreases major hepatic complications.
Copyright © 2016 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27321887     DOI: 10.1016/j.jvir.2016.04.004

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  6 in total

1.  Jejunal Migration of the Stent-Graft Used for Common Hepatic Artery Pseudoaneurysm.

Authors:  Jiwon Kim; Byung-Hee Lee
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-09-27

2.  Heparin-bonded stent graft treatment for major visceral arterial injury after upper abdominal surgery.

Authors:  Benedikt Michael Schaarschmidt; Johannes Boos; Christian Buchbender; Patric Kröpil; Feride Kröpil; Rotem Shlomo Lanzman; Guenter Fürst; Wolfram Trudo Knoefel; Gerald Antoch; Christoph Thomas
Journal:  Eur Radiol       Date:  2018-02-26       Impact factor: 5.315

3.  Post-pancreaticoduodenectomy hemorrhage: DSA diagnosis and endovascular treatment.

Authors:  Tan-Yang Zhou; Jun-Hui Sun; Yue-Lin Zhang; Guan-Hui Zhou; Chun-Hui Nie; Tong-Yin Zhu; Sheng-Qun Chen; Bao-Quan Wang; Wei-Lin Wang; Shu-Sen Zheng
Journal:  Oncotarget       Date:  2017-04-27

4.  Efficacy and hepatic complications of three endovascular treatment approaches for delayed postpancreatectomy hemorrhage: evolution over 15 years.

Authors:  Yu-Chien Chang; Kao-Lang Liu; Yu-Cheng Huang; Po-Ting Chen; Yu-Wen Tien; Yen-Heng Lin; Yeun-Chung Chang
Journal:  CVIR Endovasc       Date:  2019-10-22

5.  Risk Factors for In-hospital Mortality After Transarterial Intervention After Postpancreatectomy Hemorrhage.

Authors:  Steffen Wolk; Christoph Georg Radosa; Marius Distler; Hanns-Christoph Held; Jens-Peter Kühn; Jürgen Weitz; Thilo Welsch; Ralf-Thorsten Hoffmann
Journal:  Cardiovasc Intervent Radiol       Date:  2020-05-20       Impact factor: 2.740

Review 6.  [Interventional radiology as emergency therapy].

Authors:  Marco Armbruster; Stefan Wirth; Max Seidensticker
Journal:  Radiologe       Date:  2020-03       Impact factor: 0.635

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.